Heart Drug Fails Major Trial Despite Cutting Risk by 77%
Novartis’s drug pelacarsen cut the inherited heart-risk marker Lp(a) by 77 percent, yet patients suffered heart attacks and strokes at the same rate as those on placebo, and the company is abandoning it.
By: hammadkhaksar